• 28 Apr 26

2026 Could Be a Defining Year for POLB 001 and Oral GLP-1

2026 Could Be a Defining Year for POLB 001 and Oral GLP-1

Poolbeg Pharma PLC | POLB | 4.6 0.25 0.0%

    • 30 views

 
Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Vox Markets Weekly Wrap

Companies: SKLCTLSDGELCOIGPGBGTTGTATETEPORRTRCSASAIEYETETSHOEPXENW7LRBWAOMDCCPALMMPALPOLBATG

Poolbeg Pharma sign licence agreement with AnaBio Technologies to develop oral vaccine platform

Companies: Poolbeg Pharma PLC

Poolbeg Pharma: Sites ready, data due this summer — and Big Pharma is starting to knock

Companies: Poolbeg Pharma PLC

Poolbeg Pharma team present option agreement with University College Dublin for melioidosis vaccine

Companies: Poolbeg Pharma PLC

Poolbeg Pharma, Arecor Therapeutics, hVIVO, Ilika, Kodal Minerals, Connecting Excellence

Companies: Poolbeg Pharma PLC

Poolbeg Pharma - AI Analysis of Human Challenge Data

Companies: Poolbeg Pharma PLC

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top